Editor
Alex Zhavoronkov, left, founder and CEO of Insilico Medicine, and Feng Ren, co-CEO and chief scientific officer, at the company’s robotics lab in Suzhou, China.
Source: Insilico Medicine
The first drug fully generated by artificial intelligence entered into clinical trials with human patients this week.
Insilico Medicine, a Hong Kong-based biotech startup with more than $400 million in funding, created the drug, INS018_055, as a treatment for…
